-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aldoxorubicin in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aldoxorubicin in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aldoxorubicin in Colorectal Cancer Drug Details: Aldoxorubicin (INNO-206, DOXO-EMCH, doxorubicin-EMCH) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-8009 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-8009 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-8009 in Transitional Cell Carcinoma (Urothelial Cell...
-
Product Insights
Esophageal Diseases – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophageal Diseases - Drugs In Development, 2023’, provides an overview of the Esophageal Diseases pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Eosinophilic Esophagitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Eosinophilic Esophagitis - Drugs In Development, 2023’, provides an overview of the Eosinophilic Esophagitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Esophagitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophagitis - Drugs In Development, 2023’, provides an overview of the Esophagitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CX-904 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CX-904 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CX-904 in Solid Tumor Drug Details:CX-904 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:Abiraterone acetate (DRGT-45) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omilancor in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Omilancor in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Omilancor in Ulcerative Colitis Drug Details: Omilancor (BT-11) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acebilustat in Lymphedema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acebilustat in Lymphedema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Acebilustat in LymphedemaDrug Details:Acebilustat (formerly CTX-4430, EP-501) is under development for the treatment of bullous...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Measles [strain Edmonstons-Zagreb] + Rubella [strain RA-27]) Vaccine in Rubella (German Measles)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Measles [strain Edmonstons-Zagreb] + Rubella [strain RA-27]) Vaccine in Rubella (German Measles) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Measles [strain Edmonstons-Zagreb]...